Hanne Capital Information

Founded in 2017, Hanne Capital is a healthcare venture capital fund focusing on growth opportunities in the Greater China. The Founding Partners are industry veterans with years of senior leadership experience in leading private equity fund or world-renowned multinationals in biotech, pharma and medtech; and have accomplished significant industry milestones in their previous careers. The Hanne team consists of seasoned professionals with sharp business acumen, rich experience of investment and entrepreneurial background. Historically the founding partners have deployed over US$330 million into a number of companies and played pivotal roles in the growth of these investees. Many of our portfolios have successfully listed on renowned stock exchanges in mainland China, US, Hong Kong and Taiwan with a collective market capitalization over US$10 billion, including Hile Biopharma (SH: 603718), HEC Pharmaceutical (HK: 1558), Zai Lab Ltd ( NASDAQ: ZLAB) Zylox Medical，Endovascular Medtech ( SH: 688016) ，SinoMedical (SH: 688108) ，Venus Medtech-B（HK：2500），BeyondSpring（NASDAQ：BYSI），Anbiping Pharmaceutical Technology（SH：688393），Vessix Vascular（Acquired by Boston Scientific, NYSE: BSX），OrbiePharm and AllgensMedical（IPO filed）. We look for next generation leader companies with great growth potential in the biotech, pharma and medtech sectors, and choose to work with management teams with a track record and solid execution capabilities. We work closely with our portfolios as an extended team to create value by leveraging our broad network and deep domain expertise in growth strategy, business developments, cross-border transactions and operation improvements.